HPV vaccination among French girls and women aged 14-23 years and the relationship with their mothers' uptake of Pap smear screening: A study in general practice

Vaccine

Volumn 31, Issue 45, 2013, Pages 5243-5249

  Lutringer Magnin, D ^a,b   Cropet, C ^a   Barone, G ^a   Canat, G ^a   Kalecinski, J ^c   Leocmach, Y ^d   Vanhems, P ^b,e   Chauvin, F ^c   Lasset, C ^a,b  

^a CENTRE LÉON BÉRARD   (France)

^b LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^c INSERM   (France)

^d SANOFI PASTEUR   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

Cervical cancer screening; France; Human papillomavirus vaccination; Pap smear; Side effects

Indexed keywords

HEPATITIS B VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CONSULTATION; FEMALE; FRANCE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCREENING; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINATION;

CERVICAL CANCER SCREENING; FRANCE; HUMAN PAPILLOMAVIRUS VACCINATION; PAP SMEAR; SIDE EFFECTS;

ADOLESCENT; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; FRANCE; GENERAL PRACTICE; HUMANS; MOTHERS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PARENT-CHILD RELATIONS; YOUNG ADULT;

EID: 84885953996     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.068     Document Type: Article

References (40)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-K16.
3. Institut de Veille Sanitaire Projections de l'incidence et de la mortalité par cancer en France en 2011: col de l'utérus 2012, http://www.invs.sante.fr/ [accessed 28.12.12].
4. Echantillon généraliste de bénéficiaires (EGB) de l'assurance maladie. CNAM-TS 2012, http://www.securite-sociale.fr/IMG/pdf/obj-res2_3_pqe_maladie.pdf [accessed 28.12.12].
5. Institut de veille Sanitaire Calendrier des vaccinations et recommandations vaccinales 2012 selon l'avis du haut conseil de la santé publique (2012 vaccination schedule and recommendations from the « Haut Conseil de la santé publique » in France). Bull Epidémiol Hebd 2012, 14-15:163-187.
6. Haut Conseil de la santé publique Avis relatif à la vaccination contre les infections à papillomavirus humains des jeunes filles âgées de 14 à 23 ans (HPV vaccination recommendations from the « Haut Conseil de la santé publique » in France) 2010, http://www.fncgm.com/images/Actualites_medicales_scientifiques/vaccin_pap_hcsp_12-2010.pdf [accessed 28.12.12].
7. Trim K., Nagji N., Elit L., Roy K. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: a systematic review from 2001 to 2011. Obstet Gynecol Int 2012, 2012:921236.
8. Kessels S.J., Marshall H.S., Watson M., Braunack-Mayer A.J., Reuzel R., Tooher R.L. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012, 30:3546-3556.
9. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
10. Naleway A.L., Gold R., Drew L., Riedlinger K., Henninger M.L., Gee J. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health 2012, 21:425-432.
11. Schwarz T.F., Huang L.M., Medina D.M., Valencia A., Lin T.Y., Behre U., et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012, 50:187-194.
12. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. J Am Med Assoc 2009, 302:750-757.
13. Klein N.P., Hansen J., Chao C., Velicer C., Emery M., Slezak J., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012, 166:1140-1148.
14. Chao C., Klein N.P., Velicer C.M., Sy L.S., Slezak J.M., Takhar H., et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012, 271:193-203.
15. Chao C., Slezak J.M., Coleman K.J., Jacobsen S.J. Papanicolaou screening behavior in mothers and human papillomavirus vaccine uptake in adolescent girls. Am J Public Health 2009, 99:1137-1142.
16. Lefevere E., Hens N., Theeten H., Van den Bosch K., Beutels P., De Smet F., et al. Like mother, like daughter? Mother's history of cervical cancer screening and daughter's human papillomavirus vaccine uptake in Flanders (Belgium). Vaccine 2011, 29:8390-8396.
17. Monnat S.M., Wallington S.F. Is there an association between maternal pap test use and adolescent human papillomavirus vaccination?. J Adolesc Health 2013, 52:212-218.
18. Haesebaert J., Lutringer-Magnin D., Kalecinski J., Barone G., Jacquard A.C., Régnier V., et al. French women's knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14-18 year old daughters: a quantitative-qualitative study. BMC Public Health 2012, 12:1034.
19. Lutringer-Magnin D., Kalecinski J., Barone G., Leomach Y., Regnier V., Jacquard A.C., et al. Human papillomavirus (HPV) vaccination: perception and practice among French general practitioners in the year since licensing. Vaccine 2011, 29:5322-5328. "Personnal communication".
20. Institut National de Prévention et d'Education pour la santé Baromètre santé 2005, Attitudes et comportements de santé 2005, 331.
21. Rouzier R., Giordanella J.P. Coverage and compliance of human papilloma virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J Adolesc Health 2010, 47:237-241.
22. Laz T.H., Rahman M., Berenson A.B. An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine 2012, 30:3534-3540.
23. Ogilvie G., Anderson M., Marra F., McNeil S., Pielak K., Dawar M., et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med 2010, 7:e1000270.
24. Agius P.A., Pitts M.K., Smith A.M., Mitchell A. Human papillomavirus and cervical cancer: gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine 2010, 28:4416-4422.
25. Forster A.S., Marlow L.A., Wardle J., Stephenson J., Waller J. Understanding adolescents' intentions to have the HPV vaccine. Vaccine 2010, 28:1673-1676.
26. Smith L.M., Brassard P., Kwong J.C., Deeks S.L., Ellis A.K., Lévesque L.E. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health 2011, 11:645.
27. Dempsey A., Cohn L., Dalton V., Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010, 28:989-995.
28. Niccolai L.M., Mehta N.R., Hadler J.L. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Prev Med 2011, 41:428-433.
29. Widdice L.E., Bernstein D.I., Leonard A.C., Marsolo K.A., Kahn J.A. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics 2011, 127:77-84.
30. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc 2009, 84:864-870.
31. Dempsey A.F., Schaffer S.E., Cohn L.M. Follow-up analysis of adolescents partially vaccinated against human papillomavirus. J Adolesc Health 2012, 50:421-423.
32. Lau R.R., Quadrel M.J., Hartman K.A. Development and change of young adults' preventive health beliefs and behavior: influence from parents and peers. J Health Soc Behav 1990, 31:240-259.
33. Ashok M., Berkowitz Z., Hawkins N.A., Tangka F., Saraiya M. Recency of Pap testing and future testing plans among women aged 18-64: analysis of the 2007 Health Information National Trends Survey. J Womens Health 2012, 21:705-712.
34. Lofters A.K., Moineddin R., Hwang S.W., Glazier R.H. Predictors of low cervical cancer screening among immigrant women in Ontario, Canada. BMC Womens Health 2011, 11:20.
35. Jain N., Hennessey K. Hepatitis B vaccination coverage among U.S. adolescents, National Immunization Survey-Teen, 2006. J Adolesc Health 2009, 44:561-567.
36. Brewer N.T., Gottlieb S.L., Reiter P.L., McRee A.L., Liddon N., Markowitz L., et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis 2011, 38:197-204.
37. Reiter P.L., Cates J.R., McRee A.L., Gottlieb S.L., Shafer A., Smith J.S., et al. Statewide HPV vaccine initiation among adolescent females in North Carolina. Sex Transm Dis 2010, 37:549-556.
38. Roberts S.A., Brabin L., Stretch R., Baxter D., Elton P., Kitchener H., et al. Human papillomavirus vaccination and social inequality: results from a prospective cohort study. Epidemiol Infect 2011, 139:400-405.
39. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 2010, 171:357-367.
40. Lutringer-Magnin D., Kalecinski J., Cropet C., Barone G., Ronin V., Régnier V., Leocmach Y., Jacquard A.C., Vanhems P., Chauvin F., Lasset C. Prevention of sexually transmitted infections among girls and young women in relation to their HPV vaccination status. Eur J Public Health 2013, [Epub ahead of print].